Clinician’s Guide to Adverse Events Associated With High-Dose Interleukin-2

Von Experten verfasster Kommentar zu Kombinationstherapien mit PARP-Inhibitoren und anderen Wirkstoffen bei fortgeschrittenem Prostatakrebs von Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Commento di un esperto sulle terapie di combinazione che utilizzano inibitori PARP più altri agenti come Opzioni di cura clinica (Clinical Care Options, (CCO), nel cancro alla prostata avanzato.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

臨床ケアオプション (CCO)による、前立腺進行がんに対するRARP阻害薬と他の薬剤を使用した組み合わせ治療に関する専門家が書いたコメント

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

CCO downloadable PDF: immune checkpoint therapy for advanced urothelial cancer, perspectives from Argentina

Alejandro Nolazco, MD José Ignacio Nolazco, MD Released: March 1, 2021